- Home
- PBK vs VERU Comparison
PBK vs VERU Comparison
Compare PBK & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBK | VERU |
|---|---|---|
| Founded | N/A | 1971 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 48.2M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | PBK | VERU |
|---|---|---|
| Price | $0.52 | $2.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | ★ 471.2K | 261.5K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.42 | $0.36 |
| 52 Week High | $0.86 | $7.33 |
Technical Indicators
Market Signals| Indicator | PBK | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 37.05 |
| Support Level | $0.42 | $2.11 |
| Resistance Level | $0.85 | $2.67 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 48.91 | 9.09 |
Price Performance
Historical ComparisonAbout VERU Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.